Analysis of transcriptome characteristics of UTI therapy for cerebral injury after CA/ROSC based on RNA-seq technique

Document Type : Original Article


1 Department of Emergency, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China

2 Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China

3 Department of General Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China


Objective(s): To study the effects and mechanisms of ulinastatin (UTI) on brain injury caused by cardiac arrest/return of spontaneous circulation (CA/ROSC). 
Materials and Methods: In this study, modeling of CA/ROSC was set up in 56 Sprague Dawley (SD) rats, which were randomly divided into the model group, UTI (100000U/kg) treatment group, and control group. Each group then was divided into two subgroups: 24 hr and 72 hr. The survival rates between different groups was observed during two weeks. AimPlex multiplex immunoassays technology was performed to detect the expression of inflammatory cytokines in serum, such as IL-6 and TNF-α. RNA-sequencing (RNA-seq) transcriptome, Gene Ontology (GO), and Kyoto. Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were used to investigate the possible mechanism of UTI. Western blot and immunohistochemistry were performed to detect the expression of C-C motif chemokine ligand 2 (CCl2) and plasminogen (plg) protein expression.
Results: The survival rate of the UTI group was significantly higher than the model group during two weeks. And UTI can significantly reduce the content of IL-6 and TNF-α in serum. GO and KEGG pathway enrichment analysis revealed that differentially expressed genes mainly belonged to the IL-17 signaling pathway and neuroactive ligand-receptor interaction signaling pathway. Besides, UTI can down-regulate the expression of the CCl2 inflammatory gene and up-regulate the expression of plg in the brain tissue of CA/ROSC rats. 
Conclusion: UTI has neuroprotective effects on brain injury after CA/ROSC. And the key mechanisms belong to the regulation of immune-inflammatory response as well as the signaling molecules and interaction. 


1.    Rodríguez-Reyes H, Muñoz-Gutiérrez M, Salas-Pacheco JL. Current behavior of sudden cardiac arrest and sudden death. Arch Cardiol Mex 2020; 90: 200-206.
2.    Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. N Engl J Med 2019; 381: 2327-2337.
3.    Hosseini M, Wilson RH, Crouzet C, Amirhekmat A, Wei KS, Akbari Y, et al. Resuscitating the globally ischemic brain: TTM and beyond. Neurotherapeutics 2020; 17: 539-562.
4.    Rust R, Grönnert L, Gantner C, Enzler A, Mulders G, Weber RZ, et al. Nogo-A targeted therapy promotes vascular repair and functional recovery following stroke. PNAS 2019; 116: 14270-14279.
5.    Chen YC, Ma NX, Pei ZF, Wu Z, Do-Monte FH, Keefe S, et al. A NeuroD1 AAV-Based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol Ther 2020; 28: 217-234.
6.    Blanco-Ocampo D, Cawen FA, Álamo-Pindado LA, Negro-Demontel ML, Peluffo H. Safe and neuroprotective vectors for long-term traumatic brain injury gene therapy. Gene Ther 2020; 27: 96-103. 
7.    Da Silva SC, Feres O, Da Silva Beggiora P, Machado HR, Menezes-Reis R, Araújo JE, et al. Hyperbaric oxygen therapy reduces astrogliosis and helps to recovery brain damage in hydrocephalic young rats. Childs Nerv Syst 2018; 34: 1125-1134.
8.    Li HZ, Chen JF, Liu M, Shen J. Effect of hyperbaric oxygen on the permeability of the blood-brain barrier in rats with global cerebral ischemia/reperfusion injury. Biomed Pharmacother 2018; 108: 1725-1730. 
9.    Siponkoski ST, Martínez-Molina N, Kuusela L, Laitinen S, Holma M, Ahlfors M, et al. Music therapy enhances executive functions and prefrontal structural neuroplasticity after traumatic brain injury: evidence from a randomized controlled trial. J Neurotrauma 2020; 37: 618-634.
10.    Xia DL, Zhang H. Effects of mild hypothermia on expression of NF-E2-related factor 2 and heme-oxygenase-1 in cerebral cortex and hippocampus after cardiopulmonary resuscitation in rats. Iran J Basic Med Sci 2017; 20: 1002-1008.
11.    Lin Y, Xu D, Gao F, Zheng X. Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model. Ann Transl Med 2021; 9: 924.
12.    Lv B, Jiang XM, Wang DW, Chen J, Han DF, Liu XL. Protective effects and mechanisms of action of ulinastatin against cerebral ischemia-reperfusion injury. Curr Pharm Des 2020; 26: 3332-3340. 
13.    Meng C, Qian Y, Zhang WH, Liu Y, Song XC, Liu H, et al. A retrospective study of ulinastatin for the treatment of severe sepsis. Medicine 2020; 99: e23361.
14.    He HW, Zhang H. The efficacy of different doses of ulinastatin in the treatment of severe acute pancreatitis. Ann Palliat Med 2020; 9: 730-737.
15.    Fang S, Li P, Zhu C, Han X, Bao P, Guo W. Research progress of ulinastatin in the treatment of liver diseases. Int J Clin Exp Pathol 2020; 13: 2720-2726.
16.    Liu T, Liao XZ, Zhou MT. Ulinastatin alleviates traumatic brain injury by reducing endothelin-1. Transl Neurosci 2021; 12: 1-8.
17.    Feng X, Ma W, Chen J, Jiao W, Wang Y. Ulinastatin alleviates early brain injury after traumatic brain injury by inhibiting oxidative stress and apoptosis. Acta Cir Bras 2022; 37: e370108. 
18.    Zheng K, Lin L, Jiang W, Chen L, Zhang X, Zhang Q, et al. Single-cell RNA-seq reveals the transcriptional landscape in ischemic stroke. J Cereb Blood Flow Metab 2022; 42: 56-73. 
19.    Schmidt-Kastner R. Genomic approach to selective vulnerability of the hippocampus in brain ischemia-hypoxia. Neuroscience 2015; 309: 259-279. 
20.    Jou C, Shah R, Figueroa A, Patel JK. The role of inflammatory cytokines in cardiac arrest. J Intensive Care Med 2020; 35: 219-224.
21.    Menzebach A, Bergt S, von Waldthausen P, Dinu C, Nöldge-Schomburg G, Vollmar B. A comprehensive study of survival, tissue damage, and neurological dysfunction in a murine model of cardiopulmonary resuscitation after potassium-induced cardiac arrest. Shock 2010; 33: 189-196.
22.    Wang T, He C. TNF-αand IL-6: The Link between Immune and Bone System. Curr Drug Targets 2020; 21: 213-227.
23.    Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding. Int J Mol Sci 2021; 22: 2922. 
24.    Kunnumakkara AB, Thakur KK, Rana V, Bora B, Banik K, Khatoon E, et al. Upside and downside of tumor necrosis factor blockers for treatment of immune/inflammatory diseases. Crit Rev Immunol 2019; 39: 439-479. 
25.    Subedi L, Lee SE, Madiha S, Gaire BP, Jin M, Yumnam S, et al. Phytochemicals against TNFα-mediated neuroinflammatory diseases. Int J Mol Sci 2020; 21: 764. 
26.    Li HZ, Chen JF, Liu M, Shen J. Effect of hyperbaric oxygen on the permeability of the blood-brain barrier in rats with global cerebral ischemia/reperfusion injury. Biomed Pharmacother 2018; 108: 1725-1730. 
27.    Wang JX, Yue BJ, Zhang XH, Guo X, Sun ZL, Niu RY. Effect of exercise on microglial activation and transcriptome of hippocampus in fluorosis mice. Sci Total Environ 2021; 760: 143376. 
28.    Xiao G, Wang T, Zhuang W, Ye C, Luo L, Wang H, et al. RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways. Aging 2020; 12: 4953-4969. 
29.    Alizadeh R, Bahmanpoor Z, Jalali-Qomi S, Amiri M, Afkhami H, Khaledi M, et al. MicroRNA-targeted signaling pathways in the autism spectrum disorder: implications for early detection and targeted therapy. CNS Neurol Disord Drug Targets 2021; 20: 68-75. 
30.    Yang M, Wu XQ, Ding CB, Zhang GF, Li M, Lv LN, et al. Weighted gene co-expression network analysis identifies specific modules and hub genes related to Parkinson’s disease. Neuroreport 2021; 32: 1073-1081. 
31.    McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity 2019; 50: 892-906.
32.    Bechara R, McGeachy MJ, Gaffen SL. The metabolism-modulating activity of IL-17 signaling in health and disease. J Exp Med 2021; 218: e20202191.
33.    Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor-based signaling and implications for disease. Nat Immunol 2019; 20: 1594-1602. 
34.    Zhao X, Liu S, Yang X, Liu Y, Liu G, Fan K, et al. Cathepsin C aggravates neuroinflammation via promoting production of CCL2 and CXCL2 in glial cells and neurons in a cryogenic brain lesion. Neurochem Int 2021; 148: 105107. 
35.    Popiolek-Barczyk K, Ciechanowska A, Ciapała K, Pawlik K, Oggioni M, Mercurio D, et al. The CCL2/CCL7/CCL12/CCR2 pathway is substantially and persistently upregulated in mice after traumatic brain injury, and CCL2 modulates the complement system in microglia. Mol Cell Probes 2020; 54: 101671. 
36.    Gutiérrez IL, González-Prieto M, Caso JR, García-Bueno B, Leza JC, Madrigal JLM. Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer’s Disease: Role of CCL2. Mol Neurobiol 2019; 56: 8628-8642. 
37.    Fang JH, Chopp M, Xin HQ, Zhang L, Wang F, Golembieski W, et al. Plasminogen deficiency causes reduced angiogenesis and behavioral recovery after stroke in mice. J Cereb Blood Flow Metab 2021; 41: 2583-2592.
38.    Zhao JJ, Liu ZW, Wang B, Huang TQ, Guo D, Zhao YL, et al. Inhibiting endogenous tissue plasminogen activator enhanced neuronal apoptosis and axonal injury after traumatic brain injury. Neural Regen Res 2020; 15: 667-675.
39.    Xia YG, Pu HJ, Leak RK, Shi YJ, Mu HF, Hu XM, et al. Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury. Proc Natl Acad Sci USA 2018; 115: E9230-E9238.